Physician profile
Gregory Charles Mitchell
NPI 1326098237
$671.11
in general payments reported to CMS, 2019-2025
15 companies · $274 in 2025
The $274 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.94 · 2021: $101 · 2022: $18.45 · 2023: $52.53 · 2024: $211 · 2025: $274.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $537.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $536.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $157.66 | 2024-2025 | Zurzuvae |
| Hologic Sales and Service, LLC | $87.99 | 2022-2025 | Aptima, Novasure |
| Cumberland Pharmaceuticals, INC. | $65.95 | 2021 | |
| Phathom Pharmaceuticals, INC. | $42.61 | 2025 | Voquezna |
| Otsuka America Pharmaceutical, INC. | $40.01 | 2025 | Rexulti |
| Pfizer INC. | $39.19 | 2023-2025 | |
| Daiichi Sankyo INC. | $38.79 | 2019-2021 | |
| Biomarin Pharmaceutical INC. | $36.57 | 2024 | Voxzogo 1.2mg |
| Exact Sciences Corporation | $34.83 | 2025 | Cologuard Collection Kit |
| Abbvie INC. | $29.56 | 2023-2024 | |
| Abbott Laboratories | $25.34 | 2025 | |
| Sumitomo Pharma America, INC. | $21.45 | 2025 | Gemtesa |
| Novo Nordisk INC | $21.16 | 2023 | Wegovy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.83 | 2025 | Caplyta |
| Avion Pharmaceuticals | $11.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.